Hizentra
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Hizentra
- Generic name
- HUMAN IMMUNOGLOBULIN G
- Manufacturer
- CSL Behring AG
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 7b58f5ff-0316-49a3-b585-1f6003ddb953
- SPL ID
- 411c01a7-0ae7-45d2-8b4c-cbe99a2ba264
- Version
- 26
- Effective date
- 2023-04-20
- Source export date
- 2026-11-13
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:54:50
| Harmonized routes |
|---|
| SUBCUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125350 | derived:openfda.application_number |
| application number | BLA125350 | openfda.application_number | |
| brand name | Hizentra | openfda.brand_name | |
| generic name | HUMAN IMMUNOGLOBULIN G | openfda.generic_name | |
| manufacturer name | CSL Behring AG | openfda.manufacturer_name | |
| ndc | package | 44206-456-21 | openfda.package_ndc |
| ndc | package | 44206-452-91 | openfda.package_ndc |
| ndc | package | 44206-457-95 | openfda.package_ndc |
| ndc | package | 44206-455-93 | openfda.package_ndc |
| ndc | package | 44206-452-02 | openfda.package_ndc |
| ndc | package | 44206-454-04 | openfda.package_ndc |
| ndc | package | 44206-451-01 | openfda.package_ndc |
| ndc | package | 44206-456-94 | openfda.package_ndc |
| ndc | package | 44206-455-10 | openfda.package_ndc |
| ndc | package | 44206-451-90 | openfda.package_ndc |
| ndc | package | 44206-457-22 | openfda.package_ndc |
| ndc | package | 44206-458-96 | openfda.package_ndc |
| ndc | package | 44206-454-92 | openfda.package_ndc |
| ndc | package | 44206-458-24 | openfda.package_ndc |
| ndc | package | 44206-455-25 | openfda.package_ndc |
| ndc | package | 44206-455-97 | openfda.package_ndc |
| ndc | product | 44206-455 | openfda.product_ndc |
| ndc | product | 44206-452 | openfda.product_ndc |
| ndc | product | 44206-458 | openfda.product_ndc |
| ndc | product | 44206-451 | openfda.product_ndc |
| ndc | product | 44206-456 | openfda.product_ndc |
| ndc | product | 44206-457 | openfda.product_ndc |
| ndc | product | 44206-454 | openfda.product_ndc |
| ndc11 | package | 44206045597 | derived:openfda.package_ndc |
| ndc11 | package | 44206045621 | derived:openfda.package_ndc |
| ndc11 | package | 44206045896 | derived:openfda.package_ndc |
| ndc11 | package | 44206045694 | derived:openfda.package_ndc |
| ndc11 | package | 44206045190 | derived:openfda.package_ndc |
| ndc11 | package | 44206045492 | derived:openfda.package_ndc |
| ndc11 | package | 44206045593 | derived:openfda.package_ndc |
| ndc11 | package | 44206045101 | derived:openfda.package_ndc |
| ndc11 | package | 44206045404 | derived:openfda.package_ndc |
| ndc11 | package | 44206045824 | derived:openfda.package_ndc |
| ndc11 | package | 44206045525 | derived:openfda.package_ndc |
| ndc11 | package | 44206045202 | derived:openfda.package_ndc |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: THROMBOSIS Thrombosis may occur with immune globulin products 1-3 , including HIZENTRA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions (5.2) , and Patient Counseling Information (17) . For patients at risk of thrombosis, administer HIZENTRA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see Warnings and Precautions (5.2) ]. WARNING: THROMBOSIS See full prescribing information for complete boxed warning. Thrombosis may occur with immune globulin products, including HIZENTRA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. For patients at risk of thrombosis, administer HIZENTRA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. ( 5.1 ) Thrombosis may occur following treatment with immune globulin products, including HIZENTRA. ( 5.2 ) Aseptic meningitis syndrome has been reported with IGIV or IGSC, including HIZENTRA treatment. ( 5.3 ) Monitor renal function, including blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure. ( 5.4 ) Monitor for clinical signs and symptoms of hemolysis. ( 5.5 ) Monitor for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). ( 5.6 ) HIZENTRA is made from human blood and may contain infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.7 ) 5.1 Hypersensitivity Severe hypersensitivity reactions may occur to human immune globulin or components of HIZENTRA, such as polysorbate 80. If a hypersensitivity reaction occurs, discontinue the HIZENTRA infusion immediately and institute appropriate treatment. Individuals with IgA deficiency can develop anti-IgA antibodies and anaphylactic reactions (including anaphylaxis and shock) after administration of blood components containing IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of HIZENTRA. HIZENTRA contains ≤50 mcg/mL IgA [see Description (11) ] . 5.2 Thrombosis Thrombosis may occur following treatment with immune globulin products 1-3 , including HIZENTRA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triglycerides, or monoclonal gammopathies. For patients at risk of thrombosis, administer HIZENTRA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see Boxed Warning , Dosage and Administration (2) and Patient Counseling Information (17) ]. 5.3 Aseptic Meningitis Syndrome (AMS) AMS has been reported with use of IGIV 4 or IGSC, including HIZENTRA. The syndrome usually begins within several hours to 2 days following immune globulin treatment. AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting. Cerebrospinal fluid (CSF) studies frequently show pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL. AMS may occur more frequently in association with high doses (≥2 g/kg) and/or rapid infusion of immune globulin product. Patients exhibiting such signs and symptoms should receive a thorough neurological examination, including CSF studies, to rule out other causes of meningitis. Discontinuation of immune globulin treatment has resulted in remission of AMS within several days without sequelae. 5.4 Renal Dysfunction/Failure Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis and death may occur with use of human immune globulin products, especially those containing sucrose. 5 HIZENTRA does not contain sucrose. Ensure that patients are not volume depleted before administering HIZENTRA. For patients judged to be at risk for developing renal dysfunction, including patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs, monitor renal function and consider lower, more frequent dosing [see Dosage and Administration (2) ] . Periodic monitoring of renal function and urine output is particularly important in patients judged to have a potential increased risk of developing acute renal failure. 6 Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of HIZENTRA and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuing HIZENTRA. 5.5 Hemolysis HIZENTRA can contain blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin (Coombs') test result and hemolysis. 7,9 Delayed hemolytic anemia can develop subsequent to immune globulin therapy due to enhanced RBC sequestration, and acute hemolysis, consistent with intravascular hemolysis, has been reported. 10 Monitor recipients of HIZENTRA for clinical signs and symptoms of hemolysis. If signs and/or symptoms of hemolysis are present after HIZENTRA infusion, perform appropriate confirmatory laboratory testing. 5.6 Transfusion-Related Acute Lung Injury (TRALI) Noncardiogenic pulmonary edema may occur in patients administered human immune globulin products. 11 TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Typically, it occurs within 1 to 6 hours following transfusion. Patients with TRALI may be managed using oxygen therapy with adequate ventilatory support. Monitor HIZENTRA recipients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient's serum. 5.7 Transmissible Infectious Agents Because HIZENTRA is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. No cases of transmission of viral diseases or CJD have been associated with the use of HIZENTRA. All infections suspected by a physician possibly to have been transmitted by HIZENTRA should be reported to CSL Behring Pharmacovigilance at 1-866-915-6958. 5.8 Laboratory Tests Various passively transferred antibodies in immunoglobulin preparations may lead to misinterpretation of the results of serological testing.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (ARs) observed in ≥5% of study subjects receiving HIZENTRA were local reactions (e.g., swelling, redness, heat, pain, hematoma and itching at the infusion site), headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain (upper), migraine, arthralgia, pain, fall and nasopharyngitis. The most common adverse reactions observed in ≥5% of study subjects were local infusion site reactions, headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain (upper), migraine, arthralgia, pain, fall and nasopharyngitis. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, AR rates observed in clinical studies of a product cannot be directly compared to rates in the clinical studies of another product and may not reflect the rates observed in clinical practice. Treatment of Primary Immunodeficiency (PI) PI U.S. Study The safety of HIZENTRA was evaluated in a clinical study in the U.S. for 15 months (3-month wash-in/wash-out period followed by a 12-month efficacy period) in subjects with PI who had been treated previously with IGIV every 3 or 4 weeks. The safety analyses included 49 subjects in the intention-to-treat (ITT) population. The ITT population consisted of all subjects who received at least one dose of HIZENTRA [see Clinical Studies (14) ] . Subjects were treated with HIZENTRA at weekly median doses ranging from 66 to 331 mg/kg body weight (mean: 181.4 mg/kg) during the wash-in/wash-out period and from 72 to 379 mg/kg (mean: 213.2 mg/kg) during the efficacy period. The 49 subjects received a total of 2264 weekly infusions of HIZENTRA. Table 2 summarizes the most frequent adverse reactions (ARs) (experienced by at least 2 subjects) occurring during or within 72 hours after the end of an infusion. Local reactions were assessed by the investigators 15 to 45 minutes post-infusion and by the subjects 24 hours post-infusion. The investigators then evaluated the ARs arising from the subject assessments. Local reactions were the most frequent ARs observed, with infusion-site reactions (e.g., swelling, redness, heat, pain, and itching at the site of infusion) comprising 98% of local reactions. Table 2. Incidence of Subjects with Adverse Reactions (ARs) Excluding infections. (Experienced by 2 or More Subjects) and Rate per Infusion (ITT Population), PI U.S. Study ARs Occurring During or Within 72 Hours of Infusion AR (≥2 Subjects) Number (%) of Subjects (n=49) Number (Rate Rate of ARs per infusion. ) of ARs (n=2264 Infusions) Local reactions Includes infusion-site reactions as well as bruising, scabbing, pain, irritation, cysts, eczema, and nodules at the infusion site. 49 (100) 1322 (0.584) Other ARs: Headache 12 (24.5) 32 (0.014) Diarrhea 5 (10.2) 6 (0.003) Fatigue 4 (8.2) 4 (0.002) Back pain 4 (8.2) 5 (0.002) Nausea 4 (8.2) 4 (0.002) Pain in extremity 4 (8.2) 6 (0.003) Cough 4 (8.2) 4 (0.002) Vomiting 3 (6.1) 3 (0.001) Abdominal pain, upper 3 (6.1) 3 (0.001) Migraine 3 (6.1) 4 (0.002) Pain 3 (6.1) 4 (0.002) Arthralgia 2 (4.1) 3 (0.001) Contusion 2 (4.1) 3 (0.001) Rash 2 (4.1) 3 (0.001) Urticaria 2 (4.1) 2 (<0.001) The ratio of infusions with ARs , including local reactions, to all infusions was 1303 to 2264 (57.6%). Excluding local reactions, the corresponding ratio was 56 to 2264 (2.5%). Table 3 summarizes infusion-site reactions based on investigator assessments 15 to 45 minutes after the end of the 683 infusions administered during regularly scheduled visits (every 4 weeks). Table 3. Investigator Assessment 15 to 45 minutes following infusions administered at regularly scheduled visits (every 4 weeks). of Infusion-Site Reactions by Infusion, PI U.S. Study Infusion-Site Reaction Number For multiple infusion sites, every site was judged, but only the site with the strongest reaction was recorded. (Rate Rate of infusion-site reactions per infusion. ) of Reactions (n=683 Infusions Number of infusions administered during regularly scheduled visits. ) Edema/induration 467 (0.68) Erythema 346 (0.51) Local heat 108 (0.16) Local pain 88 (0.13) Itching 64 (0.09) Most local reactions were either mild (does not interfere with routine activities [93.4%]) or moderate (interferes somewhat with routine activities and may have warranted intervention [6.3%]) in intensity. No deaths or serious ARs occurred during the study. Two subjects withdrew from the study due to ARs. One subject experienced a severe infusion-site reaction one day after the third weekly infusion, and the other subject experienced moderate myositis. PI European Study In a clinical study conducted in Europe, the safety of HIZENTRA was evaluated for 10 months (3-month wash-in/wash-out period followed by a 7-month efficacy period) in 51 subjects with PI who had been treated previously with IGIV every 3 or 4 weeks or with IGSC weekly. Subjects were treated with HIZENTRA at weekly median doses ranging from 59 to 267 mg/kg body weight (mean: 118.8 mg/kg) during the wash-in/wash-out period and from 59 to 243 mg/kg (mean: 120.1 mg/kg) during the efficacy period. The 51 subjects received a total of 1831 weekly infusions of HIZENTRA. Table 4 summarizes the most frequent ARs (experienced by at least 2 subjects) occurring during or within 72 hours after the end of an infusion. Local reactions were assessed by the subjects between 24 and 72 hours post-infusion. The investigators then evaluated the ARs arising from the subject assessments. Table 4. Incidence of Subjects with Adverse Reactions (ARs) Excluding infections. (Experienced by 2 or More Subjects) and Rate per Infusion, PI European Study ARs Occurring During or Within 72 Hours of Infusion AR (≥2 Subjects) Number (%) of Subjects (n=51) Number (Rate Rate of ARs per infusion. ) of ARs (n=1831 Infusions) Local reactions Includes infusion-related reaction; infusion-site mass; infusion/injection-site erythema, hematoma, induration, inflammation, edema, pain, pruritus, rash, reaction, swelling; infusion-site extravasation, nodule; puncture-site reaction. 24 (47.1) 105 (0.057) Other ARs: Headache 9 (17.6) 20 (0.011) Rash 4 (7.8) 4 (0.002) Pruritus 4 (7.8) 13 (0.007) Fatigue 3 (5.9) 5 (0.003) Abdominal pain, upper 2 (3.9) 3 (0.002) Arthralgia 2 (3.9) 2 (0.001) Erythema 2 (3.9) 4 (0.002) Abdominal discomfort 2 (3.9) 3 (0.002) Back pain 2 (3.9) 2 (0.001) Hematoma 2 (3.9) 3 (0.002) Hypersensitivity 2 (3.9) 4 (0.002) The proportion of subjects reporting local reactions decreased over time from approximately 20% following the first infusion to <5% by the end of the study. Three subjects withdrew from the study due to ARs of mild to moderate intensity. One subject experienced infusion-site pain and infusion-site pruritus; the second subject experienced infusion-site reaction, fatigue, and feeling cold; and the third subject experienced infusion-site reaction and hypersensitivity. Biweekly (Every 2 Weeks) or Frequent (2 To 7 Times per Week) Dosing No data regarding ARs are available for these alternative HIZENTRA dosing regimens because no clinical trials using these regimens were conducted. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) PATH Study The safety of 2 doses of HIZENTRA (0.2 g/kg body weight or 0.4 g/kg body weight) versus placebo was evaluated in the 24-week subcutaneous (SC) treatment period of the PATH (Polyneuropathy AND Treatment with Hizentra) study in subjects with CIDP who had been treated previously with IGIV [see Clinical Studies (14.2) ] . The dose was administered once a week in 2 infusion sessions conducted on 1 or 2 consecutive day(s). The safety population included 172 subjects. Table 5 summarizes the most frequent ARs that occurred in ≥5% of subjects treated with HIZENTRA and at a higher frequency than placebo. The overall AR rates were similar in the 0.2 g/kg body weight and 0.4 g/kg body weight HIZENTRA dose groups (50.9% and 46.6%, respectively) and higher than placebo (33.3%). The most frequent ARs were local infusion site reactions. Local reactions were more frequent among subjects who received the 0.4 g/kg body weight dose than among subjects who received the 0.2 g/kg body weight dose (29.3% and 19.3%, respectively). The exposure-adjusted rate of local reactions per subject remained greater in the 0.4 g/kg body weight dose group compared to the 0.2 g/kg body weight dose group after adjusting for the greater mean duration of exposure to HIZENTRA in the 0.4 g/kg body weight dose group (129 days) compared to that of the 0.2 g/kg body weight dose group (119 days). All local reactions were either mild (does not interfere with routine activities [94.5%]) or moderate (interferes somewhat with routine activities and may have warranted intervention [5.5%]) in intensity and the frequency tended to decrease over time. No subject withdrew because of local reaction. One serious AR, allergic dermatitis was reported in the 0.2 g/kg body weight HIZENTRA group which started at SC Week 9 and lasted 15 days. One subject withdrew from the study due to a non-serious AR, fatigue. Table 5. CIDP SC Treatment Period – ARs Occurring in ≥5% of Subjects Treated with HIZENTRA and at a Higher Frequency than Placebo-Treated Subjects Placebo 0.2 g/kg HIZENTRA 0.4 g/kg HIZENTRA Number (%) of Subjects n=57 Number of Events (Rate/Infusion) n=1514 Number of infusions. Number (%) of Subjects n=57 Number of Events (Rate/Infusion) n=2007 Number (%) of Subjects n=58 Number of Events (Rate/Infusion) n=2218 AR = adverse reaction; SC = subcutaneous. Local Reactions Includes infusion site erythema, infusion site swelling, infusion site pain, infusion site induration, infusion site warmth, infusion site hematoma, and infusion site pruritus. 4 (7.0) 7 (0.005) 11 (19.3) 54 (0.027) 17 (29.3) 49 (0.022) Headache 2 (3.5) 2 (0.001) 4 (7.0) 5 (0.002) 4 (6.9) 4 (0.002) Nasopharyngitis 1 (1.8) 1 (<0.001) 4 (7.0) 6 (0.003) 2 (3.4) 2 (<0.001) Fatigue 1 (1.8) 1 (<0.001) 5 (8.8) 5 (0.002) 0 0 Upper respiratory tract infection 2 (3.5) 2 (0.001) 3 (5.3) 3 (0.001) 2 (3.4) 2 (<0.001) Fall 0 0 3 (5.3) 8 (0.004) 1 (1.7) 1 (<0.001) Back Pain 1 (1.8) 1 (<0.001) 3 (5.3) 4 (0.002) 1 (1.7) 1 (<0.001) Arthralgia 1 (1.8) 1 (<0.001) 3 (5.3) 4 (0.002) 1 (1.7) 1 (<0.001) Pain in Extremity 0 0 1 (1.8) 1 (<0.001) 3 (5.2) 3 (0.001) Hypertension was reported in 2 subjects (3.5%) in the 0.2 g/kg HIZENTRA group, 2 subjects (3.4%) in the 0.4 g/kg group, and zero subjects in the placebo group. Systemic adverse reactions in the 13-week IGIV Restabilization Period of the study for subjects also randomized and treated with HIZENTRA during the 24-week subcutaneous treatment period (N=115) occurred at a rate of 0.098 (956 infusions) relative to a rate of 0.027 (4225 infusions) during treatment with HIZENTRA in the IGSC period of the study. The systemic adverse reaction rate per infusion for HIZENTRA was 3.6-fold lower than the corresponding rate for IGIV. The exposure-adjusted rate for systemic adverse reactions in the 13-week single-arm IGIV Restabilization Period of the study for subjects also randomized and treated with HIZENTRA during the 24-week subcutaneous treatment period (N=115) was 0.075 reactions per week, relative to an exposure-adjusted rate of 0.052 reactions per week during treatment with HIZENTRA in the IGSC period of the study. The exposure-adjusted systemic adverse reaction rate for HIZENTRA was 31% lower than the corresponding rate for IGIV. However, this difference should be interpreted with caution, because there was no parallel group of subjects receiving placebo during the period of IGIV treatment. PATH Extension Study The PATH Extension study was a multicenter, 48-week, open-label extension study that evaluated the long -term safety and efficacy of HIZENTRA 0.2 g/kg and 0.4 g/kg doses, per body weight, in the maintenance treatment of CIDP in subjects who either completed or were being successfully rescued from CIDP relapse with IGIV in the PATH study. A total of 82 subjects were enrolled. Of these, 66 (80.5%) subjects completed the study, and 16 (19.5%) subjects discontinued. In the study, 30.1% of subjects in the HIZENTRA 0.2 g/kg group and 51.4% of subjects in the 0.4 g/kg group experienced adverse reactions. Similar to the PATH study, the most frequent ARs were local infusion site reactions, and local reactions were more frequent among subjects who received the 0.4 g/kg body weight dose than among subjects who received the 0.2 g/kg body weight dose (18.1% and 9.6%, respectively). Of all the local reactions, 1 subject had 3 severe reactions (interrupts routine activities or may require intensive therapeutic intervention [7.5%]) with the 0.4 g/kg dose; the rest were either mild (85.0%) or moderate (7.5%). Two subjects withdrew because of local reactions. The total exposure was 25.1 subject years in the HIZENTRA 0.2 g/kg group and 38.7 subject years in the 0.4 g/kg group. The mean duration of exposure was 125.8 (range 1 to 330) days in the HIZENTRA 0.2 g/kg group and 196.1 (range 1 to 330) days in the 0.4 g/kg group. 6.2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. HIZENTRA The following adverse reactions have been identified during postmarketing use of HIZENTRA. This list does not include reactions already reported in clinical studies with HIZENTRA [ see Adverse Reactions (6.1) ] . Infusion reactions: Allergic-anaphylactic reactions such as swollen face or tongue and pharyngeal edema, pyrexia, chills, dizziness, hypertension/changes in blood pressure, malaise, tachycardia, flushing. Cardiovascular: Chest discomfort (including chest pain) Respiratory: Dyspnea Neurological: Tremor, burning sensation General disorders and administration site conditions: Infusion site ulcer, infusion site necrosis Immune Globulin Products The following adverse reactions have been reported during postmarketing use of immune globulin products: 5 Infusion reactions: Wheezing, rigors, myalgia Renal: Osmotic nephropathy Respiratory: Apnea, Acute Respiratory Distress Syndrome (ARDS), cyanosis, hypoxemia, pulmonary edema, bronchospasm Cardiovascular: Cardiac arrest, vascular collapse, hypotension Neurological: Coma, loss of consciousness, seizures, aseptic meningitis syndrome Integumentary: Stevens-Johnson syndrome, epidermolysis, erythema multiforme, dermatitis (e.g., bullous dermatitis) Hematologic: Pancytopenia, leukopenia, hemolysis, positive direct antiglobulin (Coombs') test Gastrointestinal: Hepatic dysfunction To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
adverse reactions table
<table width="75%"><caption>Table 2. Incidence of Subjects with Adverse Reactions (ARs)<footnote ID="t2f1">Excluding infections.</footnote> (Experienced by 2 or More Subjects) and Rate per Infusion (ITT Population), PI U.S. Study</caption><col width="40%" align="left" valign="middle"/><col width="25%" align="center" valign="middle"/><col width="35%" align="center" valign="middle"/><thead><tr><th styleCode="Lrule Rrule"/><th styleCode="Rrule Botrule" colspan="2">ARs<footnoteRef IDREF="t2f1"/> Occurring During or Within 72 Hours of Infusion</th></tr><tr><th styleCode="Lrule Rrule">AR (≥2 Subjects)</th><th styleCode="Rrule" align="center">Number (%) of Subjects (n=49)</th><th styleCode="Rrule">Number (Rate<footnote>Rate of ARs per infusion.</footnote>) of ARs (n=2264 Infusions)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Local reactions<footnote>Includes infusion-site reactions as well as bruising, scabbing, pain, irritation, cysts, eczema, and nodules at the infusion site.</footnote></td><td styleCode="Rrule">49 (100)</td><td styleCode="Rrule">1322 (0.584)</td></tr><tr><td styleCode="Lrule Rrule">Other ARs:</td><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr><td styleCode="Lrule Rrule"> Headache</td><td styleCode="Rrule">12 (24.5)</td><td styleCode="Rrule">32 (0.014)</td></tr><tr><td styleCode="Lrule Rrule"> Diarrhea</td><td styleCode="Rrule">5 (10.2)</td><td styleCode="Rrule">6 (0.003)</td></tr><tr><td styleCode="Lrule Rrule"> Fatigue</td><td styleCode="Rrule">4 (8.2)</td><td styleCode="Rrule">4 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Back pain</td><td styleCode="Rrule">4 (8.2)</td><td styleCode="Rrule">5 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Nausea</td><td styleCode="Rrule">4 (8.2)</td><td styleCode="Rrule">4 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Pain in extremity</td><td styleCode="Rrule">4 (8.2)</td><td styleCode="Rrule">6 (0.003)</td></tr><tr><td styleCode="Lrule Rrule"> Cough</td><td styleCode="Rrule">4 (8.2)</td><td styleCode="Rrule">4 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Vomiting</td><td styleCode="Rrule">3 (6.1)</td><td styleCode="Rrule">3 (0.001)</td></tr><tr><td styleCode="Lrule Rrule"> Abdominal pain, upper</td><td styleCode="Rrule">3 (6.1)</td><td styleCode="Rrule">3 (0.001)</td></tr><tr><td styleCode="Lrule Rrule"> Migraine</td><td styleCode="Rrule">3 (6.1)</td><td styleCode="Rrule">4 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Pain</td><td styleCode="Rrule">3 (6.1)</td><td styleCode="Rrule">4 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Arthralgia</td><td styleCode="Rrule">2 (4.1)</td><td styleCode="Rrule">3 (0.001)</td></tr><tr><td styleCode="Lrule Rrule"> Contusion</td><td styleCode="Rrule">2 (4.1)</td><td styleCode="Rrule">3 (0.001)</td></tr><tr><td styleCode="Lrule Rrule"> Rash</td><td styleCode="Rrule">2 (4.1)</td><td styleCode="Rrule">3 (0.001)</td></tr><tr><td styleCode="Lrule Rrule"> Urticaria</td><td styleCode="Rrule">2 (4.1)</td><td styleCode="Rrule">2 (<0.001)</td></tr></tbody></table>
adverse reactions table
<table width="75%"><caption>Table 3. Investigator Assessment<footnote>15 to 45 minutes following infusions administered at regularly scheduled visits (every 4 weeks).</footnote> of Infusion-Site Reactions by Infusion, PI U.S. Study</caption><col width="48%" align="left" valign="bottom"/><col width="52%" align="center" valign="bottom"/><thead><tr><th styleCode="Lrule Rrule">Infusion-Site Reaction</th><th styleCode="Rrule">Number<footnote>For multiple infusion sites, every site was judged, but only the site with the strongest reaction was recorded.</footnote> (Rate<footnote>Rate of infusion-site reactions per infusion.</footnote>) of Reactions (n=683 Infusions<footnote>Number of infusions administered during regularly scheduled visits.</footnote>)</th></tr></thead><tbody><tr><td styleCode="Lrule Rrule">Edema/induration</td><td styleCode="Rrule">467 (0.68)</td></tr><tr><td styleCode="Lrule Rrule">Erythema</td><td styleCode="Rrule">346 (0.51)</td></tr><tr><td styleCode="Lrule Rrule">Local heat</td><td styleCode="Rrule">108 (0.16)</td></tr><tr><td styleCode="Lrule Rrule">Local pain</td><td styleCode="Rrule">88 (0.13)</td></tr><tr><td styleCode="Lrule Rrule">Itching</td><td styleCode="Rrule">64 (0.09)</td></tr></tbody></table>
adverse reactions table
<table width="75%"><caption>Table 4. Incidence of Subjects with Adverse Reactions (ARs)<footnote ID="t4f1">Excluding infections.</footnote> (Experienced by 2 or More Subjects) and Rate per Infusion, PI European Study</caption><col width="40%" align="left" valign="top"/><col width="25%" align="center" valign="top"/><col width="35%" align="center" valign="top"/><thead><tr styleCode="Botrule"><th styleCode="Lrule Rrule"/><th styleCode="Rrule" colspan="2">ARs<footnoteRef IDREF="t4f1"/> Occurring During or Within 72 Hours of Infusion</th></tr><tr><th styleCode="Lrule Rrule">AR (≥2 Subjects)</th><th styleCode="Rrule" align="center">Number (%) of Subjects (n=51)</th><th styleCode="Rrule">Number (Rate<footnote>Rate of ARs per infusion.</footnote>) of ARs (n=1831 Infusions)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Local reactions<footnote>Includes infusion-related reaction; infusion-site mass; infusion/injection-site erythema, hematoma, induration, inflammation, edema, pain, pruritus, rash, reaction, swelling; infusion-site extravasation, nodule; puncture-site reaction.</footnote></td><td styleCode="Rrule">24 (47.1)</td><td styleCode="Rrule">105 (0.057)</td></tr><tr><td styleCode="Lrule Rrule">Other ARs:</td><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr><td styleCode="Lrule Rrule"> Headache</td><td styleCode="Rrule">9 (17.6)</td><td styleCode="Rrule">20 (0.011)</td></tr><tr><td styleCode="Lrule Rrule"> Rash</td><td styleCode="Rrule">4 (7.8)</td><td styleCode="Rrule">4 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Pruritus</td><td styleCode="Rrule">4 (7.8)</td><td styleCode="Rrule">13 (0.007)</td></tr><tr><td styleCode="Lrule Rrule"> Fatigue</td><td styleCode="Rrule">3 (5.9)</td><td styleCode="Rrule">5 (0.003)</td></tr><tr><td styleCode="Lrule Rrule"> Abdominal pain, upper</td><td styleCode="Rrule">2 (3.9)</td><td styleCode="Rrule">3 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Arthralgia</td><td styleCode="Rrule">2 (3.9)</td><td styleCode="Rrule">2 (0.001)</td></tr><tr><td styleCode="Lrule Rrule"> Erythema</td><td styleCode="Rrule">2 (3.9)</td><td styleCode="Rrule">4 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Abdominal discomfort</td><td styleCode="Rrule">2 (3.9)</td><td styleCode="Rrule">3 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Back pain</td><td styleCode="Rrule">2 (3.9)</td><td styleCode="Rrule">2 (0.001)</td></tr><tr><td styleCode="Lrule Rrule"> Hematoma</td><td styleCode="Rrule">2 (3.9)</td><td styleCode="Rrule">3 (0.002)</td></tr><tr><td styleCode="Lrule Rrule"> Hypersensitivity</td><td styleCode="Rrule">2 (3.9)</td><td styleCode="Rrule">4 (0.002)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.